MedCity News January 20, 2025
AstraZeneca’s Datroway, an antibody drug conjugate (ADC), is now FDA approved for advanced cases of breast cancer that is HR positive and HER2 negative. Datroway targets TROP2, the same cancer protein addressed by Trodelvy, a Gilead Sciences ADC also approved for breast cancer.
A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another product to fill out an oncology portfolio that’s a key part of its revenue growth strategy.
The regulatory decision announced late Friday covers the treatment of adults with advanced cases of breast cancer that is HR positive and HER2 negative and cannot be removed by surgery. Also, these cancers...
Today's Sponsors
Today's Sponsor